FRIDAY 24th JUNE 2022 – 15.30-16.30 HRS (CET)
Klaas P. Zuideveld, Ph.d Chief Executive Officer, Versameb and Professor Roger Dmochowski of Vanderbilt University to highlight the need for a therapeutic solution in SUI.
RNA therapeutics are a new class of medicines that have a broad applicability targeting disease relevant proteins. Proteins are large and complex molecules that play a critical role in the body’s capacity to be healthy. Currently, most approved drugs are small molecules and protein biologics, which can only target a very limited number of proteins or genes. Our RNA-based therapeutics can be used to selectively trigger protein overexpression or downregulation, for single or multiple protein targets with one RNA construct. This uncovers new therapeutic possibilities for previously undruggable targets.
FRIDAY 24th JUNE 2022 – 15.30-16.30 HRS (CET)
Klaas P. Zuideveld, Ph.d Chief Executive Officer, Versameb and Professor Roger Dmochowski of Vanderbilt University to highlight the need for a therapeutic solution in SUI.
RNA therapeutics are a new class of medicines that have a broad applicability targeting disease relevant proteins. Proteins are large and complex molecules that play a critical role in the body’s capacity to be healthy. Currently, most approved drugs are small molecules and protein biologics, which can only target a very limited number of proteins or genes. Our RNA-based therapeutics can be used to selectively trigger protein overexpression or downregulation, for single or multiple protein targets with one RNA construct. This uncovers new therapeutic possibilities for previously undruggable targets.